Explicyte Immuno-Oncology - Cancer Immunotherapy CRO Services
Cancer Immunotherapy CRO Services
In vitro
Tumor killing
Tumor sensitization
Activation & immune checkpoint inhibition
Antibody-dependent cell cytotoxicity (ADCC)
Tumor antigen-specific killing
Bispecific T cell engager (BiTE) killing
Antibody-Drug Conjugate (ADC) killing
Immuno-modulation
Immune cell activation
Immune cell migration
Mixed lymphocyte reaction (MLR)
Macrophage assays
TLS-GC reaction
Cytokine release syndrome
Featured
Xenium for cells
In Vivo
Responsiveness to immunotherapies
PD-1/PD-L1 axis blockade
CTLA-4 blockade
Immunization
Syngeneic tumor models
Breast Cancer : 4T1
Breast Cancer : EMT6
Colon Cancer : CT26
Colon Cancer : MC38
Glioblastoma : GL261
Lung Cancer : Lewis LLC1
Pancreatic Cancer : Pan02
Renal Cancer : Renca
Sarcoma : MCA-205
Translational
Services
Custom tumor tissue sourcing
Target validation
Preclinical immune profiling
Biomarker discovery & testing
Image analysis
Technological platforms
Quantitative digital pathology
Digital spatial profiling
Whole-transcriptome spatial biology
Single-cell spatial transcriptomics
Single-cell RNA Seq
Proteomics
Flow cytometry
Featured service
TLS detection & evaluation
Spatial transcriptomics
Single-cell analysis
Spatial biology
About
About Explicyte
Science
News
Careers
Contact us
Toggle menu
Contact us
Multispecific drug candidates characterization - Preclinical CRO services
Explicyte Immuno-Oncology
>
CRO Services
>
In vitro
>
Protected: Multispecific drug candidates characterization – Preclinical CRO services
This content is password-protected. To view it, please enter the password below.
Password:
WordPress Lightbox
